Contribution of PEPFAR-Supported HIV and TB Molecular Diagnostic Networks to COVID-19 Testing Preparedness in 16 Countries
Emerg. infect. dis. (Online)
; 28(13): 1-10, Dec. 2022. tab.
Article
in English
| RSDM
| ID: biblio-1523115
Responsible library:
MZ1.1
ABSTRACT
The US President's Emergency Plan for AIDS Relief (PEPFAR) supports molecular HIV and tuberculosis diagnostic networks and information management systems in low- and middle-income countries. We describe how national programs leveraged these PEPFAR-supported laboratory resources for SARS-CoV-2 testing during the COVID-19 pandemic. We sent a spreadsheet template consisting of 46 indicators for assessing the use of PEPFAR-supported diagnostic networks for COVID-19 pandemic response activities during April 1, 2020, to March 31, 2021, to 27 PEPFAR-supported countries or regions. A total of 109 PEPFAR-supported centralized HIV viral load and early infant diagnosis laboratories and 138 decentralized HIV and TB sites reported performing SARS-CoV-2 testing in 16 countries. Together, these sites contributed to >3.4 million SARS-CoV-2 tests during the 1-year period. Our findings illustrate that PEPFAR-supported diagnostic networks provided a wide range of resources to respond to emergency COVID-19 diagnostic testing in 16 low- and middle-income countries.
Full text:
Available
Collection:
National databases
/
MZ
Database:
RSDM
Main subject:
HIV Infections
/
COVID-19
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
Africa
Language:
English
Journal:
Emerg. infect. dis. (Online)
Year:
2022
Document type:
Article
Institution/Affiliation country:
CDC Center for Global Health/AO
/
CDC Center for Global Health/CD
/
CDC Center for Global Health/CM
/
CDC Center for Global Health/DO
/
CDC Center for Global Health/ET
/
CDC Center for Global Health/KE
/
CDC Center for Global Health/MZ
/
CDC Center for Global Health/NA
/
CDC Center for Global Health/SD
/
CDC Center for Global Health/ZM